Good day, and welcome to the IMAX Fourth Quarter and Full-Year 2017 Earnings Conference Call. All participants are currently in a listen-only mode. Following the presentation, we will conduct a question-and-answer session. As a reminder, today's conference is being recorded. At this time, I'd like to turn the conference over to Michael Mougias. Please go ahead. Michael Mougias - IMAX Corp.: Thank you, Rene. Good afternoon, and thank you for joining us on today's fourth quarter and full-year 2017 earnings conference call. Joining me today is our CEO, Rich Gelfond; our CFO, Patrick McClymont; and our Head of Entertainment, Greg Foster, who each have prepared remarks and will be available for Q&A. Also joining us is Rob Lister, Chief Legal Officer. Today's conference call is being webcast in its entirety on our website. A replay of the webcast will be made available shortly after the call. In addition, the full text of our fourth quarter release and the slide presentation accompanying today's call have been posted on the Investor Relations section of our website. At the conclusion of this call, our historical excel model and guidance information will be posted on the website as well. I would like to remind you of the following information regarding forward-looking statements. Our comments and answers to your questions on this call, as well as the accompanying slide deck may include statements that are forward-looking and that they pertain to future results or outcomes. Actual future results or occurrences may differ materially from these forward-looking statements. Please refer to our SEC filings for a more detailed discussion of some of the factors that could affect our future results and outcomes. During today's call, references may be made to certain non-GAAP financial measures as defined by Regulation G of the Securities and Exchange Commission. Discussion of management's use of these measures and the definition of these measures, as well as reconciliations to adjusted net income, adjusted EPS and adjusted EBITDA as defined by our credit facility are contained in this afternoon's press release. With that, let me now turn the call over to Rich Gelfond. Richard L. Gelfond - IMAX Corp.: Thanks, Mike. During the second half last year, we made efforts to refine our global programming strategy, reduced our cost structure and reanalyzed our new business efforts. Our primary objective was to facilitate more operating leverage throughout our business. I'm pleased to say that several refinements across various areas of the company have had encouraging early results as demonstrated by our stronger box office performance in the second half of 2017 and into 2018. More specifically, in the second half of last year following our refinements, IMAX domestic box office grew 17% compared to an exhibitor industry decline of 6%. In China, box office grew roughly 7% and in our international ex-China segment, box office was up over 19%. Overall, IMAX fourth quarter global box office was up roughly 13% compared to the prior year. And more recently, we broke company records with the release of Black Panther, which achieved $34 million of the IMAX box office in its four-day opening weekend and another $15 million last weekend. The film has grossed more than $50 million in IMAX screens worldwide and that doesn't include key markets such as China and Japan, which we'll open the film shortly. In China, during the recent Chinese New Year holiday, we grew box office 60% over the four-day opening weekend compared to the prior year, and even more encouraging over the seven-day holiday period, our box office grew to $27 million, up 74%. Interestingly, the performance of the three films vary day-to-day. Monster Hunt 2 started out the strongest. However, Operation Red Sea quickly gained ground, while Detective Chinatown (sic) [Detective Chinatown 2] (00:04:01) held steady throughout the holiday. The varying performance of these films over the course of Chinese New Year, highlights the significance of our multi-film strategy in China. Had we played just one film, we do not believe our performance would have been nearly as strong. It is also worth mentioning that the past two weekends, our network has exhibited all of the top four global films in the world. Overall, our box office results over the past eight months underpin our continued value proposition for blockbuster movies and highlight that overall industry box office performance is not always indicative of our performance. The blockbuster IMAX business can be quite different than the conventional cinema business. In addition to compelling content, a key component of our recent performance, our results also reflected tangible benefits from several of our recently announced revenue and cost initiatives. You may recall that one of our initiatives was to program more 2D versions of films across our domestic network rather than 3D. To that end, Blade Runner 2049 and Justice League were programmed exclusively in IMAX 2D last quarter, and more than half of Thor: Ragnarok and Star Wars: The Last Jedi were programmed in 2D. Recently, Black Panther had about 80% of its domestic showings in 2D. While we only recently implemented this strategy, the preliminary result of this decision have been encouraging. And our intention is to continue to play more 2D versions of films across our domestic slate. Additionally, we've been focusing on increasing our programming flexibility, particularly in China. As outlined on our last earnings call, we are re-mastering an increasing number of Chinese titles, specifically during bigger box office weekends or weekends where there is no single dominant film, such as during Chinese New Year. For example, we played four local language titles across our network during the blackout period in December. And as previously mentioned, we exhibited three local language titles during Chinese New Year. We believe providing our exhibitor partners with optionality will increase the revenue power of our network and enable us to be more nimble, reducing the chances of missing potential hits. In addition to our revenue initiatives, we have continued to streamline our cost structure. We believe that this effort has already has had a positive effect on our ability to drive operating leverage. OpEx for the fourth quarter, which includes SG&A and R&D, excluding stock comp, was down slightly year-over-year. For the full year 2017, OpEx was flat compared to 2016. And as we look to 2018, we intend to continue with our disciplined approach to cost management. For instance, we anticipate this year's consolidated OpEx to be essentially flat with that of 2017 and 2016. Turning to our network growth, we signed deals for 23 new theaters in the fourth quarter, bringing total new theater signings for the year to 170. Keep in mind, this is on top of the record 314 new signings that we achieved in 2016. These signings not only facilitate future network growth and earnings, they also serve as a testament to our exhibitor partners' continued demand for IMAX. As a result, our backlog consisted of 494 new systems at year-end. Of this backlog, roughly 63% is in China and roughly 28% in other international markets. Additionally, we are optimistic about our opportunities to expand into newer markets. For example, Saudi Arabia has recently lifted its ban on commercial movie theaters, which could make that an attractive market for us. We also recently signed our largest single deal in Ecuador, a five-theater agreement with Supercines, a top exhibitor in the country. We also continue to make progress in India. Our backlog in the country now consist of 13 screens on top of the 12 existing in that market. And we're continuing to field interest from exhibitors in that market. Furthermore, exhibitor consolidation has in the past served as a conduit to future signings activity. And to that end, we think Cineworld's acquisition of Regal could facilitate not only additional signings but other strategic benefits as well. We have a longstanding relationship with Cineworld, and they clearly understand the benefits of IMAX and bringing incremental revenue to a multiplex, leveraging our product as a core component of their strategy. All-in-all, we remain encouraged by our continued signings momentum as well as our prospects for future signings. On the installation front, we installed 69 new theatres in the fourth quarter, bringing our full year 2017 installs to 165. As a result, our commercial network now consists of 1,272 screens, more than two-thirds of which are in international markets. I think it is also worth noting that Wanda represented 57 of our installs last year, roughly twice their targeted amount. This continued expansion, coupled with the recent investments in Wanda from the likes of Tencent and Alibaba underscores our continued optimism in our partnership. Overall, growing the network continues to be a foremost priority. We believe a bigger footprint is essential to generating more box office and ultimately more earnings long term. This is particularly true given the various deal structures we offer clients. For example, sales type leases and hybrid arrangements, which represent 57% of our backlog, come with little or no upfront investment. Thus, the ongoing contribution margin is almost completely incremental. And when analyzing full JV opportunities, which do require a capital investment, we clearly weigh the potential ROI against our cost of capital for each location. We believe if we can provide an ROI in excess of our cost of capital, we will pursue that investment. Nonetheless, it is important to recognize the impact that our growing presence in emerging markets such as China, India, Russia and Latin America has had on metrics, such as per screen averages. For instance, our average ticket price in China is roughly $8, a 45% discount to our average domestically. In India, the average IMAX ticket price is roughly $7. While these markets present us with different economics, we view them as an attractive opportunity to grow box office, regardless of their potential impact on global PSAs. Remember, box office, not PSAs, drive revenue. Our focus as an organization therefore needs to be on generating more box office, in absolute terms. If we are effective at maintaining a stable cost structure, every additional box office dollar we generate should come with very little incremental cost. Turning to new business, we currently have seven pilot virtual reality centers open around the world. Our plan is to use these pilot locations to collect data, test different technologies and experiment with various types of content before making any formal decisions on the future of this initiative. At this time, we do not anticipate opening additional VR centers or making meaningful future investments in the initiative. And on the original content front, we continue to believe that leveraging our network as a platform to launch and distribute content remains an attractive opportunity, particularly during shoulder periods. However, we recognize the hit miss nature of the content business and therefore we'll aim to serve as more of a distributor rather than a principle when looking at alternative content, similar to what we've done in 2016 with Game of Thrones. While there may be select opportunities to invest in content namely through funds such as the China Film Fund, we do not anticipate making big financial investments in content going forward. All-in-all our approach to new business going forward will be less capital intensive in nature. We continue to believe there are attractive ways we can leverage our network brand and global awareness that do not require upfront capital. Potential opportunities that we find attractive would include distributing and premiering content or potential licensing opportunities. Nonetheless, we anticipate significantly less spend on new business this year. And on the marketing front, we're in the midst of finalizing an updated brand campaign and we look forward to sharing it with you in the near future. Lastly, I would also like to mention that IMAX China which just published its full year results also announced it received board approval to initiate an annual dividend in the amount of $0.04 per share or roughly $14 million per year at the current share count. This announcement underscores IMAX China's strong cash position and our confidence in the company's long-term growth prospects and cash flow generation. Keep in mind, IMAX Corporation owns roughly 70% of IMAX China and as a result, we received an annual dividend payment in the range of about $10 million. In summary, the initiatives we began implementing in the second have had encouraging early results over the past eight months. Looking ahead, our primary focus remains profitably growing our footprint of theaters and seeking ways to further differentiate our format amongst consumers. While growth in smaller markets could pressure average network PSAs, we anticipate the asset-light nature of our business coupled with our cost control efforts and continued demand for new IMAX theaters positions us well to drive future operating leverage. And on the box office front, our domestic performance over the past eight months coupled with our recent results in China, following our programming refinements help demonstrate that for the right film IMAX is the place to be. With that, I'll turn it over to Greg. Greg Foster - IMAX Corp.: Thanks, Rich, and good afternoon. We generated global box office of $977 million in 2017, up slightly from 2016. We saw healthy box office growth in regions such as India, which grew 78%; France, which grew 36%; Russia, which was up 29%; and Japan, which grew 18%, all compared to 2016. In fact, our single strongest performing screen last year was in Japan, delivering box office of over $5 million in the 12-month period. Looking ahead, with almost 30% of our backlog slated for markets outside the U.S. and China, we expect these regions to become a bigger part of our overall box office results over time. As Rich highlighted, we continue to see the benefits of programming more 2D versions of films domestically. As you know, we began implementing this broad strategy in the summer of 2017, and have since ramped it up even more. In fact, every domestic IMAX release, since Dunkirk, has been programmed either entirely in 2D or had a significant percentage of 2D showings in our domestic network. We believe this programming change has contributed to stronger market share across numerous films. For our average opening weekend, indexing in the first half of 2017 was 9.6%. In the second half after implementing these refinements, our average indexing jumped to 13.1%. Another effort we made is to re-master more titles. As we pointed out on our last call, most of our films will be allotted just one week runs. We believe this reduces our exposure to potential drops in week two, while also keeping content on screen fresh. One additional point that I'd like to highlight on this front is related to premium VOD. We're often asked by investors how the potential for shorter windows may impact our business. Overall, our belief is that it won't have a significant impact provided we're playing most of our films for one or two weeks. Moreover, the films that are generally being targeted by initiatives such as PVOD, are generally not the tentpole/blockbuster titles that generate the abundance of IMAX box office. Regardless, premium VOD still remains a theoretical conversation at this time. Moving along in China, we intend to re-master roughly twice as many Chinese titles this year. This serves a couple of benefits. First, as Rich pointed out, it provides us with more optionality which is important given the difficulty in predicting the dominant title during certain weekends. And secondly, it allows us to program more local titles in tier 3, tier 4 and tier 5 cities in China where consumers tend to prefer local content. Another key effort is the use of IMAX cameras and expanded aspect ratio, specially formatted, if you will, for IMAX releases. We often refer to this as IMAX DNA. Working with filmmakers at the early stages of film production is an important component of IMAX's value proposition. It's something that only IMAX does and the benefits are clear. We tend to over-index on titles that leverage our proprietary cameras and/or aspect ratio. Our best example of this is anything related to Chris Nolan, who has perfected this strategy for both his films and our benefit. On that front, we've seen many in the next generation of important directors start to take advantage of our exclusive DNA for their blockbuster films. For example, Denis Villeneuve, director of Blade Runner 2049; and Taika Waititi, Director of Thor: Ragnarok, both leveraged IMAX technology for the first time last year. This year, our new partner, Ryan Coogler, the director behind Marvel Studios' Black Panther, leveraged IMAX's exclusive aspect ratio for almost an hour of footage and the results have been fantastic. Our exclusive DNA is such an important component of our offering, which is why I'm thrilled to announce several pillar titles that will feature our exclusive DNA. First, Venom, a Marvel title from Sony, will feature select sequences with expanded aspect ratio exclusively formatted for IMAX coming this October. Secondly, Damien Chazelle, the director of La La Land is directing Universal's First Man, the story of Neil Armstrong, which also comes out in October. Damien filmed select sequences of First Man in IMAX, which gives the space-themed film a terrific look for our cinemas. I'm also thrilled to announce that Disney's Lion King, which comes out in July of 2019 and is directed by our longtime partner, Jon Favreau, will feature roughly 30 minutes of key sequences in our aspect ratio. And lastly, I'm excited to announce that Wonder Woman 2, which comes out in the second half of 2019, will be shot with IMAX film cameras in select sequences. This Warner Brothers DC production, the sequel of the global juggernaut from 2017, is directed by Patti Jenkins and produced by Chuck Roven and Rebecca Oakley Roven. And we couldn't be more excited that IMAX has been chosen to be a part of the film's design. And of course, as we've already announced, Marvel Studios' Avengers: Infinity War, which is directed by the Russo Brothers, is the first movie to be filmed entirely with the IMAX digital cameras and comes out this spring. Our efforts to work with filmmakers and studios is a core aspect of our company strategy and rest assured there's more to come. Lastly, we continue to work with our exhibitor partners to reseat and modernize older IMAX theaters. Currently, we've reseated roughly 70 theaters across our domestic network. And generally, we've seen improved performance from these screens. We intend to continue to work with our partners on updating our network with more modern comfortable seating; importantly, new theaters that we install are generally coming with plush rockers or other premium seating from the get go. Turning to the film slate for a moment, I'm pleased to announce a number of additional titles hitting IMAX screens in the future. On the Disney front in addition to Lion King in 2019, I'm also pleased to announce that Frozen 2 and Artemis Fowl will be released in IMAX in 2019; and additionally in select theaters this September, Warner Brothers' The Nun will come out in IMAX. In 2019, Warner's and DC Shazam and IT 2 will receive IMAX runs. And in 2020, Godzilla vs. Kong will hit IMAX screens. Keep in mind, these are all new releases on top of the films that we've already announced. Overall, we remain optimistic that a combination of better and differentiated content coupled with a refined programming strategy and a growing international presence will have tangible benefits to our box office results. With that, I'll now turn the call over to Patrick. Patrick S. McClymont - IMAX Corp.: Thank you, Greg, and good afternoon, everyone. As Rich highlighted in his opening remarks, we invested a considerable amount of time last year evaluating and addressing several challenges facing our business. We focused on revenues, cost of sales, SG&A and new business spend identified several areas for improvement. While we continue to evaluate additional ways to optimize the business, we believe the company is better positioned today because the efforts we made last year. Looking at our results, we continue to see strong installation and signings activity as demonstrated on slide 5. We installed 69 new theatres last quarter, bringing our total new installations for 2017 to 165. We signed agreements for an additional 23 new theaters in the fourth quarter, bringing our total 2017 new system signings to 170 new systems. Broken down by deal type, we signed agreements for 35 full JVs, 50 hybrid JVs and 85 sales type leases in 2017. As you know, under the latter two arrangements, which represented over three quarters of our total signings, we are not required to invest any upfront capital. In fact, we make a margin upfront and then benefit from the ongoing box office performance, which comes with limited costs and no capital charge to cover. We generally seek out hybrid JVs and sales type deals in emerging markets or markets with reduced box office predictability. And with regards to full JVs, which do require IMAX capital, we continue to weigh the potential returns of these screens against our cost of capital. To quantify our approach, if we assume our cost of capital is around 15%, we estimate that a full JV theater needs to produce at least $500,000 in annual box office to achieve returns in excess of our cost of capital. We are often compared to our exhibitor partners. However, it is important to remember, IMAX is a different business model with different financial attributes. We believe our asset-light network growth approach is attractive, particularly as we continue to control the cost side of the equation. Turning to our financial results, please flip to slide 6. Total revenue in the fourth quarter came in at $126 million. Network business revenue was $54 million; theater business revenue was $56 million; and new business revenue, primarily related to ABC airing the last seven episodes of Inhumans, was $13 million. Excluding the impact from new business, our core gross profit for the fourth quarter came in at $63 million or 56% of revenues. On slide 8, you can see our 2017 total revenues were $381 million. Full year revenue from our network business was $183 million, revenue from our theater business was $155 million, and new business contributed $25 million last year. Excluding the impact from new business, our total revenue was $356 million, and gross profit was $201 million or 56% of revenues. In the fourth quarter, SG&A, excluding stock-based compensation, was down 12% to $21 million. This decrease is largely attributable to the cost reduction exercise we announced in June. R&D for the quarter came in at $6 million, a $1.5 million increase over 2016, which reflects the continued development of our commercial laser product. We also recognized a restructuring charge related to our cost reduction initiative of $2 million in the fourth quarter. This was roughly $1 million above the guidance we provided on the Q3 call and reflects several contractual agreements that actualized at the high end of our initial estimates. Our full year SG&A, excluding stock-based compensation, was down 4% to $90 million. R&D came in at $21 million, an increase of $4.5 million over 2016. In addition to laser, we also recognized expenses related to the development of the VR camera over the year. Our tax rate for the quarter was 65%, which resulted in a year-end tax rate of 56%. Please note these figures reflect the one-time impact from U.S. tax reform enacted in December. As a result of this legislation, we incurred a discrete tax expense of $9.3 million. This one-time charge resulted from the provisional re-measurement and write-down of the company's U.S. deferred tax assets and liabilities. Excluding this one-time charge, our effective tax rate for fourth quarter would have been 26.9% and full year 2017 would have been 24.9%. Consolidated GAAP net income, which includes the impact from new business, came in at $4.8 million or $0.08 per share in the quarter. For the year, our consolidated GAAP net income was $2.3 million or $0.04 per share. Please note, our GAAP net income figure include charges as a result of our cost restructuring initiative and the recent tax reform. These charges impacted our full year GAAP net income per share by $0.25 and $0.14 respectively. Our adjusted net income for the quarter, which adds back the one-time restructuring and tax charge and stock-based compensation, was $21.8 million in the quarter or $0.34 per share. For the year, adjusted net income was $40.5 million or $0.62 per share. Core operating income, excluding the impact from new initiatives and other one-time restructuring charge, was $75.2 million in 2017 and $1.15 per share, a 15% increase over 2016. The net impact of our new business investments was $19.8 million in 2017, $1.8 million above our previous guidance. This was primarily the result of our recognizing higher-than-anticipated losses associated with Inhumans and our VR initiative. For a breakdown of our adjusted net income calculations, please refer to slide 13. On slide 14, you can see adjusted EBITDA for the quarter came in at $56 million. This resulted in full year adjusted EBITDA of $138 million. Please note, pursuant to the terms of our credit agreement, impairment and amortization expenses associated with Inhumans are treated as add backs in determining adjusted EBITDA. However, we believe that excluding any impact of our investment in Inhumans provides a more meaningful evaluation of the company's adjusted EBITDA. As a result, we presented both metrics to facilitate comparisons against future and prior periods. Adjusted EBITDA on the fourth quarter and full year came in at $42 million and $126 million respectively, excluding any impact from Inhumans. Please note, our net income figures include the full dilution from Inhumans, and thus, only EBITDA reflected add backs associated with the investment. Lastly, I would like to run through our guidance for 2018 and remind you that a summary of this guidance as well as an updated historical Excel model will be available on our IR website at the conclusion of this call. Beginning with installations, we anticipate installing roughly 145 new theaters this year. Of this, we expect roughly 55 to be sales type, 65 to be full JV and 25 to be hybrid JV. For the first quarter, we expect to install roughly 11 new screens, of which we expect eight sales type, two full JV and one hybrid JV. We continue to believe our installations for the year will follow historic patterns and be weighted towards the back half. On the expense side, we anticipate DMR cost of sales to be between $40 million and $42 million this year. This increase over 2017 is primarily due to our projecting more re-mastered films during the year. On the OpEx front, which includes SG&A plus R&D less stock comp, we expect to be essentially flat compared to 2017, despite strategic investment in areas such as marketing and systems infrastructure. Stock compensation is expected to be around $22.5 million for the year. We remain actively focused on cost containment and continue to pursue additional opportunity to reduce our expense structure. We expect to incur less than $1 million of additional charges this year related to our June 2017 restructuring. Investments in new business, which will primarily consist of the operation of our seven pilot VR centers in 2018 and our home initiative, is expected to have a pre-tax impact of $8 million to $9 million. This compares to the pre-tax impact of $31.5 million last year, which primarily reflect the dilution from Marvel's Inhumans. In effect, we expect the impact of new business on operating income to be down almost 75% compared to last year. Turning to our tax expense, we anticipate our full-year effective tax rate to be approximately 24%, largely in line with prior years. Included in this 24%, our potential discrete adjustments in the neighborhood of $1 million, a large portion of which we anticipate recognizing in the first quarter. Given we are a Canadian domiciled company and earn a small percentage of our revenues in the U.S., going forward, we do not expect to see a meaningful impact to our P&L as a result of the recent tax reform. I'd also like to briefly address the impact of FASB's recent revenue recognition standard on IMAX. For the most part, we do not anticipate the new standards to have a material impact on our reporting. The biggest change for us will occur on our IMAX systems contingent rent line within the network business. This item is related to overages we received from certain sales type theaters. Going forward, we'll have to present value, the estimated impact and book these revenues upfront in the sales and sales type lease line. This could slightly increase the average sale price recognized on our STL line while slightly reducing the revenue on the contingent rent line in the network business. There will not be any changes to DMR, full JVs or hybrid JV revenue recognition. To close, our focus in 2018 is on increasing the earnings power of our core business. We expect the combination of our revenue initiatives, continued focus on cost control and less new business spend to improve our ability to generate operating leverage. We continue to seek ways of enhancing our business and believe there are still areas we can optimize. Nonetheless, we are encouraged with many of the early results and look forward to the year ahead. With that, I'll turn the call over to the operator for Q&A.